Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Beijing Huaguan Biotechnology

Request full access

Provides high-quality integrated drug research and development services for customers

ChinaFounded 2016Biotech & Life Sciences

About Beijing Huaguan Biotechnology

Beijing Huaguan Biotechnology Co., Ltd., operating under the brand Chempion, is a vertically integrated biopharmaceutical enterprise established in 2018 with headquarters in Beijing's Haidian District. The company was founded by Dr. Chen Jian, a seasoned professional in the pharmaceutical industry. Dr. Chen holds a doctorate from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, and completed postdoctoral studies at the University of Rouen in France. His extensive background includes participation in the establishment of PPDai's Beijing operations and substantial experience in both innovative drug research and development and industrial-scale production, which forms the technical foundation of the company. Since its inception, the company has undergone significant expansion, establishing a network of four R&D centers in Beijing, Nanjing, Suzhou, and Chongqing. A pivotal milestone was the 2023 acquisition of Inner Mongolia Jingdong Pharmaceutical, which now serves as its GMP-compliant active pharmaceutical ingredient (API) and key starting materials (KSMs) manufacturing base. This strategic growth has been supported by multiple funding rounds, including investments from notable entities such as Tsinghua University's Hotung Health Fund, Zhongguancun Science City Fund, and publicly listed companies like Sihuan Pharmaceutical and Xiamen Kingdomway Group. The firm's business model is centered on providing comprehensive, integrated services across the entire pharmaceutical value chain, from preclinical research to post-launch supply. Its core operations are built upon three distinct technology platforms: an advanced antibody-drug conjugate (ADC) platform, a complex molecule synthesis platform, and a platform combining continuous flow and enzymatic catalysis technologies. This infrastructure enables the company to serve a diverse clientele, including developers of innovative drugs, generic pharmaceutical manufacturers, and companies in the broader health and wellness sector. Revenue is generated by supplying materials such as APIs and intermediates, as well as offering technical services for drug development and registration.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
20.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Investment activity
1 company, latest Aug 2023
Capital deployed
$48M
Preferred round
SERIES A
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Sep 2022 $14M $55M Hua Ze Jinling · Peakview Capital · Science City · Hetang Venture Capital Management (Beijing) ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Beijing Huaguan Biotechnology website traffic

Latest recorded traffic for Beijing Huaguan Biotechnology is 1.1K monthly website visits, up 746.2% over the last three months.

Latest monthly visits1.1K 3-month web change+746.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Beijing Huaguan Biotechnology in its local ecosystem

Live from Dealroom

The Beijing Huaguan Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Hua Ze Jinling
  • Peakview Capital
  • Science City
  • Hetang Venture Capital Management (Beijing)
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Beijing Huaguan Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Beijing Huaguan Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.